Enrique Conterno, FibroGen
FDA adcomm to review FibroGen’s chronic kidney disease drug in July
The FDA said Thursday that its Cardiovascular and Renal Drugs Advisory Committee of outside experts will convene on July 15 to review the safety and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
